Preemptive treatment with oral ganciclovir for pediatric renal transplantation

Area of Science:

• Pediatric Nephrology
• Infectious Diseases
• Transplantation Immunology

Background:

• Cytomegalovirus (CMV) infection is a significant risk in pediatric renal transplant recipients.
• Ganciclovir prophylaxis is standard, but preemptive treatment strategies are evolving.
• Early detection of CMV is crucial for preventing complications and graft dysfunction.

Purpose of the Study:

• To evaluate the efficacy and safety of preemptive oral ganciclovir for CMV infection in children post-renal transplantation.
• To assess the utility of quantitative antigenemia (pp68) as an early diagnostic marker for CMV.
• To determine the impact of CMV infection and preemptive treatment on graft function and rejection.

Main Methods:

• Prospective study of 42 children following renal transplantation receiving IV ganciclovir prophylaxis.
• Regular monitoring using quantitative CMV antigenemia (pp68) and cultures (blood, urine, throat).
• Treatment with IV or oral ganciclovir based on infection status and symptoms.

Main Results:

• CMV infection detected in 52.4% of children within 44 days post-transplant; 5 symptomatic cases.
• Positive CMV antigenemia was the earliest indicator in most cases.
• Preemptive oral ganciclovir in asymptomatic cases was safe and effective, with no disease progression or resistance.
• No acute graft rejection or renal dysfunction observed; 1-year glomerular filtration rates were comparable between infected and non-infected groups.

Conclusions:

• Preemptive oral ganciclovir is a safe and effective strategy for managing CMV infection in pediatric kidney transplant patients.
• Quantitative CMV antigenemia monitoring is a sensitive and early method for detecting and controlling CMV.
• Effective CMV management preserves renal graft function and prevents complications in this vulnerable population.